The historical rank and industry rank for Tissue Regenix Group's Days Payable or its related term are showing as below:
FRA:LSW'
s Days Payable Range Over the Past 10 Years
Min: 31.67 Med: 69.83 Max: 3697.8
Current: 104.03
During the past 13 years, Tissue Regenix Group's highest Days Payable was 3697.80. The lowest was 31.67. And the median was 69.83.
FRA:LSW's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 113.76
vs FRA:LSW: 104.03
Tissue Regenix Group's Days Payable
increased
from Jun. 2024 (78.82) to Jun. 2025 (111.83).
It may suggest that Tissue Regenix Groupdelayed paying its suppliers.
Tissue Regenix Group Days Payable Related Terms
Tissue Regenix Group Days Payable Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Tissue Regenix Group's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a Days Payable of 111.83 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tissue Regenix Group and its competitors. This is 60% above median its historical median of 69.83. Over the past decade, Tissue Regenix Group's Days Payable has ranged from 31.67 to 3,697.80.
Is Tissue Regenix Group's Days Payable too high?
Tissue Regenix Group's current Days Payable of 111.83 is 60% above median its 10-year median of 69.83. Over the past 10 years, this metric has ranged from a low of 31.67 to a high of 3,697.80. The Biotechnology industry median Days Payable is 113.76. Tissue Regenix Group's value of 111.83 is 1.7% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Days Payable compare to VRTX and REGN?
Tissue Regenix Group's Days Payable of 111.83 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 113.76. Tissue Regenix Group's value of 111.83 is 1.7% below this benchmark. Historically, Tissue Regenix Group's own Days Payable has ranged from 31.67 to 3,697.80 over the past decade. While the company's 10-year median is 69.83 vs. the industry median of 113.76, Tissue Regenix Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Days Payable of 111.83 is 1.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Days Payable is 111.83, which is 60% above median its own 10-year median of 69.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Days Payable of 111.83. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Days Payable is 111.83, which is 60% above median its 10-year median of 69.83 and 1.7% below the Biotechnology industry median of 113.76. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Days Payable is 111.83 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Days Payable: 111.83 (60% above median its 10-year median of 69.83)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 1.7% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
